Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Eye tests under the microscope for blinding disease

NCT ID NCT03845218

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 18, 2026 · Updated 6 times

Summary

This completed study looked at how well different eye tests can track changes in retinitis pigmentosa (RP), a group of blinding eye diseases. Researchers tested 49 people with RP and healthy volunteers using exams like vision tests, retinal imaging, and electrical signal recordings. The goal was to find which tests are most reliable for measuring disease progression, which could help design better future treatment trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help design better clinical trials for retinitis pigmentosa treatments by identifying the most reliable tests.
What could go wrong
This was a small, observational study with no treatment tested. Results may not apply to all RP patients or lead directly to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

49 people

The number who actually took part.

Started

Sep 2019

Finished

Jul 2023

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Up to 120 participants aged 12 or older with a diagnosis of RP. Up to 30 healthy volunteers.@@@@@@

Ages

12 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA for RP Participants: To be eligible, the following inclusion criteria must be met, where applicable. * Participant must be 12 years of age or older. * Participant (or legal guardian) must understand and sign the protocol s informed consent document. * Participant must have evidence of RP as defined by characteristic ERG responses, visual fields, clinical exam and /or genetic testing. INCLUSION CRITERIA FOR HEALTHY VOLUNTEERS: To be eligible, the following inclusion criteria must be met: 1. Participant must be 18 years of age or older. 2. Participant must understand and sign the protocol s informed consent document. 3. Participant must not have evidence of RP. EXCLUSION CRITERIA FOR ALL PARTICIPANTS: A participant is not eligible if any of the following exclusion criteria are present. * Participant is actively receiving study therapy in another investigational study. * Participant is started on (or changed dosage of) topical or systemic carbonic anhydrase inhibitor (CAI) treatment in the three months prior to enrollment. * Participant is expected to be unable to comply with study procedures or follow-up visits. * Participant has evidence of an ocular disease other than RP in either eye that may confound the outcome of the study (e.g., diabetic retinopathy with ten or more hemorrhages or microaneurysms, uveitis, pseudovitelliform macular degeneration, severe myopia). * Participant is taking ocular or systemic medications known to be toxic to the lens, retina or optic nerve (e.g., ethambutol, chloroquine, or hydroxychloroquine). * Participant has a condition that would preclude participation in the study (e.g., unstable medical status including blood pressure and glycemic control) by interfering with the participant s ability to engage in the required protocol evaluation and testing and/or comply with study visits. * Participant is an NIH employee associated with this study. * Participant is unable or unwilling to give informed consent that includes use of medical records and clinical samples for current and future research.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Retinitis pigmentosa are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.